In this video, Dr. Nicholas David James discusses the results of the STAMPEDE trial, which tested front-line docetaxel combined with hormonal therapy in patients with advanced, hormone-naive prostate cancer.
Nicholas James, MD
Advertisement
Articles by Nicholas James, MD
Advertisement
Latest Updated Articles
STAMPEDE: Front-Line Docetaxel Prolongs Survival in Metastatic Prostate CancerPublished: June 4th 2015 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Casdatifan Monotherapy Achieves Clinical Activity in Late-Line Kidney Cancer
2
How Will RLTs Be Integrated Into the Prostate Cancer Treatment Paradigm?
3
Dato-DXd Improves Survival in Recurrent Inoperable/Metastatic TNBC
4
Intravesical Mitomycin Produces Enduring Efficacy Across NMIBC Trials
5
